Chimeric Antigen Receptor T-Cell Therapy: More Than an Anti-Cancer Drug

Area of Science:

• Immunotherapy
• Cellular Therapy
• Oncology
• Autoimmunity
• Virology
• Transplantation Immunology

Background:

• Chimeric antigen receptor (CAR) T-cell therapy initially targeted CD19 and B-cell maturation antigen for hematological malignancies, achieving significant success.
• The application of CAR T-cell therapy has expanded to B-cell-mediated autoimmune diseases, showing potential for long-lasting symptom remission.
• Unselective targeting of B cells necessitates the development of precise immunotherapies capable of distinguishing between pathogenic and protective B cells.

Purpose of the Study:

• To review the expanded applications of CAR T-cell therapy in autoimmunity, virology, and transplantation.
• To highlight the development of antigen-specific CARs for precise cell depletion.
• To discuss the adaptation of CAR technology for regulatory T cells (Tregs) and its implications.

Main Methods:

• Review of existing literature on CAR T-cell therapy applications.
• Discussion of antigen-specific CAR design and modified CARs incorporating autoantigens.
• Exploration of CAR T-cell and CAR Treg applications in various disease models and clinical settings.

Main Results:

• CAR T-cell therapy demonstrates efficacy in treating B-cell-mediated autoimmune diseases and viral infections.
• Antigen-specific CARs enable selective depletion of target cell subpopulations.
• CAR Tregs offer potential for inducing tolerance in autoimmune diseases, graft-versus-host disease, and transplant rejection.

Conclusions:

• CAR T-cell and CAR Treg therapies hold significant promise for treating a range of conditions beyond cancer.
• The development of antigen-specific CARs and CAR Tregs represents a crucial advancement in precision immunotherapy.
• Addressing and resolving safety concerns associated with CAR-based therapies is essential for their widespread clinical adoption.